SCHEMBL1934732

SCHEMBL1934732

CC(C)(C)OC(=O)N1CCC(CC(=O)Nc2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.56
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
GPR119 Q8TDV5 1/20 0.52
GLS O94925 2/20 0.52
CETP P11597 1/20 0.51
PTPN2 P17706 1/20 0.51
PTPN1 P18031 1/20 0.51
PTPN6 P29350 1/20 0.51
F13A1 P00488 1/20 0.51
TGM2 P21980 1/20 0.51
TGM1 P22735 1/20 0.51
TGM3 Q08188 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
ALDH1A1 P00352 2/20 0.48
HTT P42858 2/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1936856 0.90 GPR119 (0.58) USP30MEN1KMT2AGPR119CETP
SCHEMBL2539468 0.89 GPR119 (0.67) MEN1KMT2AGPR119PTPN2PTPN1
SCHEMBL13930867 0.88 PTPN2 (0.57) MEN1KMT2AGPR119GLSCETP
SCHEMBL13930868 0.86 EPHX2 (0.61) USP30GPR119GLSCETPPTPN2
SCHEMBL1946598 0.84 PTPN2 (0.72) MEN1KMT2APTPN2PTPN1PTPN6
SCHEMBL13930870 0.84 GPR119 (0.58) KMT2AGPR119GLSCETPPTPN2
SCHEMBL16825852 0.84 FPR2 (0.63) KMT2AGPR119GLSCETPPTPN2
SCHEMBL4965158 0.83 L3MBTL1 (0.67) GPR119GLSCETPPTPN2PTPN1
SCHEMBL13930863 0.83 PTPN2 (0.57) GPR119GLSCETPPTPN2PTPN1
SCHEMBL13930857 0.83 KDM4E (0.61) GPR119GLSCETPPTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212997-A1 PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2011-09-01 US disclosed
EP-2331505-A2 PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2011-06-15 EP disclosed
WO-2010023197-A2 NOVEL PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212997-A1 PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 USP30 2500/4885MEN1 2618/4885KMT2A 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.